Since p53 status is reported to be often mutated in malignant tumors, a relatively even distribution of 10B in tumors with mutant-type rather than wild-type normal tissue can be expected, leading to the usefulness of BNCT in the treatment of malignant tumors [63]. Here, TP53 is linked to cancer.